Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, gives an overview of the current CAR-T climate in the field of multiple myeloma. Dr Raje highlights the results of the KarMMa study (NCT03361748), CARTITUDE-1 (NCT03548207), and EVOLVE (NCT03430011), all evaluating different BCMA-targeting CAR T-cell therapies that show activity in multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
Current CAR-T climate in multiple myeloma
Теги
Speaker: Noopur RajeInstitution: Massachusetts General HospitalEvent: VJVirtualEvent: EBMT 2020Format: InterviewSubject: Multiple MyelomaMedicines: LenalidomideMedicines: PomalidomideField: Immuno-OncologyField: CAR-T & Cellular TherapyMedicines: CAR-TMedicines: DaratumumabMedicines: IsatuximabMedicines: Idecabtagene vicleucelTrial: KarMMaNCT03361748Trial: CARTITUDE-1Trial: EVOLVEMedicines:Orvacabtagene autoleucelField: Gene therapy
